Show simple item record

dc.contributor.authorGriesinger, F
dc.contributor.authorCamidge, DR
dc.contributor.authorKim, HR
dc.contributor.authorAhn, MJ
dc.contributor.authorYang, JCH
dc.contributor.authorHan, JY
dc.contributor.authorHochmair, M
dc.contributor.authorLee, H
dc.contributor.authorDelmonte, A
dc.contributor.authorCompelo, MRG
dc.contributor.authorKim, DW
dc.contributor.authorFelip, E
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorSpire, A
dc.contributor.authorGettinger, SN
dc.contributor.authorTiseo, M
dc.contributor.authorLin, HM
dc.contributor.authorNi, QH
dc.contributor.authorZhang, PK
dc.contributor.authorPopat, S
dc.date.accessioned2020-04-22T07:25:06Z
dc.date.available2020-04-22T07:25:06Z
dc.date.issued2020en
dc.identifier.citationGriesinger F, Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, et al. Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC. Oncology Research and Treatment. 2020;43:232-en
dc.identifier.urihttp://hdl.handle.net/10541/622896
dc.language.isoenen
dc.titleUpdated results from the phase 3 ALTA-1L trial of brigatinib (BRG) vs. crizotinib (CRZ) in ALK inhibitor-naive advanced ALK plus NSCLCen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentPius-Hospital Oldenburg, University of Oldenburg, Oldenburgen
dc.identifier.journalOncology Research and Treatmenten
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record